Last 12 months
Inside the activity.
0 purchase rows · 75 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 11 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 6 |
| Feb 2026 | 0 | 8 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 4 |
| May 2026 | 0 | 5 |
| Jun 2026 | 0 | 7 |
| Jul 2026 | 0 | 4 |
| Aug 2026 | 0 | 15 |
| Sep 2026 | 0 | 7 |
| Oct 2026 | 0 | 2 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 11, 2022 Filed Mar 15, 2022 01:46 UTC |
Pletcher Brett AEVP,Corp Affairs & Gen Counsel
|
SaleCommon Stock | 3,634 | $58.24 | $211,644.16 |
DisclosureSEC source: 0001127602-22-009215 · form4.xml · nonDerivative · entry 4 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,576 Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:14 UTC |
Mercier JohannaChief Commercial Officer
|
GrantRestricted Stock Unit · Derivative | 27,840 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-009207 · form4.xml · derivative · entry 7 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,783 Underlying: Common Stock · 27,840 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F3 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:14 UTC |
Mercier JohannaChief Commercial Officer
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 171,670 | $0.00 Strike: $57.92 | $0.00 |
DisclosureSEC source: 0001127602-22-009207 · form4.xml · derivative · entry 6 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,670 Underlying: Common Stock · 171,670 shares Expires 2032-03-10 F4 · derivative.exercise_date: The shares subject to the option have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:14 UTC |
Mercier JohannaChief Commercial Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 3,962 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-009207 · form4.xml · derivative · entry 5 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,943 Underlying: Common Stock · 3,962 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F3 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:14 UTC |
Mercier JohannaChief Commercial Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 3,025 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-009207 · form4.xml · derivative · entry 4 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,905 Underlying: Common Stock · 3,025 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:14 UTC |
Mercier JohannaChief Commercial Officer
|
Tax withholdingCommon Stock | 3,221 | $57.92 | $186,560.32 |
DisclosureSEC source: 0001127602-22-009207 · form4.xml · nonDerivative · entry 3 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,544 Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:14 UTC |
Mercier JohannaChief Commercial Officer
|
Exercise / conversionCommon Stock | 3,962 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-009207 · form4.xml · nonDerivative · entry 2 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,765 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:14 UTC |
Mercier JohannaChief Commercial Officer
|
Exercise / conversionCommon Stock | 3,025 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-009207 · form4.xml · nonDerivative · entry 1 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,803 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:20 UTC |
Parsey MerdadChief Medical Officer
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 171,670 | $0.00 Strike: $57.92 | $0.00 |
DisclosureSEC source: 0001127602-22-009209 · form4.xml · derivative · entry 7 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,670 Underlying: Common Stock · 171,670 shares Expires 2032-03-10 F4 · derivative.exercise_date: The shares subject to the option have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:20 UTC |
Parsey MerdadChief Medical Officer
|
GrantRestricted Stock Unit · Derivative | 27,840 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-009209 · form4.xml · derivative · entry 6 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,317 Underlying: Common Stock · 27,840 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. F3 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:20 UTC |
Parsey MerdadChief Medical Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 4,157 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-009209 · form4.xml · derivative · entry 5 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,477 Underlying: Common Stock · 4,157 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. F3 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:20 UTC |
Parsey MerdadChief Medical Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 3,455 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-009209 · form4.xml · derivative · entry 4 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,634 Underlying: Common Stock · 3,455 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:20 UTC |
Parsey MerdadChief Medical Officer
|
Tax withholdingCommon Stock | 3,505 | $57.92 | $203,009.60 |
DisclosureSEC source: 0001127602-22-009209 · form4.xml · nonDerivative · entry 3 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,265 Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:20 UTC |
Parsey MerdadChief Medical Officer
|
Exercise / conversionCommon Stock | 4,157 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-009209 · form4.xml · nonDerivative · entry 2 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,770 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:20 UTC |
Parsey MerdadChief Medical Officer
|
Exercise / conversionCommon Stock | 3,455 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-009209 · form4.xml · nonDerivative · entry 1 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,613 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:30 UTC |
Wilfong Diane E.SVP, Controller & CAO
|
GrantRestricted Stock Unit · Derivative | 5,610 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-009211 · form4.xml · derivative · entry 7 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,356 Underlying: Common Stock · 5,610 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F3 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:30 UTC |
Wilfong Diane E.SVP, Controller & CAO
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 18,850 | $0.00 Strike: $57.92 | $0.00 |
DisclosureSEC source: 0001127602-22-009211 · form4.xml · derivative · entry 6 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,850 Underlying: Common Stock · 18,850 shares Expires 2032-03-10 F4 · derivative.exercise_date: The shares subject to the option have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:30 UTC |
Wilfong Diane E.SVP, Controller & CAO
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,272 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-009211 · form4.xml · derivative · entry 5 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,746 Underlying: Common Stock · 1,272 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F3 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:30 UTC |
Wilfong Diane E.SVP, Controller & CAO
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,025 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-009211 · form4.xml · derivative · entry 4 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,018 Underlying: Common Stock · 2,025 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the yearly anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the yearly anniversary of the date of grant until fully vested. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:30 UTC |
Wilfong Diane E.SVP, Controller & CAO
|
Tax withholdingCommon Stock | 935 | $57.92 | $54,155.20 |
DisclosureSEC source: 0001127602-22-009211 · form4.xml · nonDerivative · entry 3 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,581 Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:30 UTC |
Wilfong Diane E.SVP, Controller & CAO
|
Exercise / conversionCommon Stock | 1,272 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-009211 · form4.xml · nonDerivative · entry 2 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,516 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:30 UTC |
Wilfong Diane E.SVP, Controller & CAO
|
Exercise / conversionCommon Stock | 2,025 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-009211 · form4.xml · nonDerivative · entry 1 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,244 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:46 UTC |
Pletcher Brett AEVP,Corp Affairs & Gen Counsel
|
Exercise / conversionRestricted Stock Unit · Derivative | 3,130 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-009215 · form4.xml · derivative · entry 6 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,301 Underlying: Common Stock · 3,130 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F3 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:46 UTC |
Pletcher Brett AEVP,Corp Affairs & Gen Counsel
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,593 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-009215 · form4.xml · derivative · entry 5 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,431 Underlying: Common Stock · 2,593 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:46 UTC |
Pletcher Brett AEVP,Corp Affairs & Gen Counsel
|
Tax withholdingCommon Stock | 2,089 | $57.92 | $120,994.88 |
DisclosureSEC source: 0001127602-22-009215 · form4.xml · nonDerivative · entry 3 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,210 Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:46 UTC |
Pletcher Brett AEVP,Corp Affairs & Gen Counsel
|
Exercise / conversionCommon Stock | 3,130 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-009215 · form4.xml · nonDerivative · entry 2 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,299 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:46 UTC |
Pletcher Brett AEVP,Corp Affairs & Gen Counsel
|
Exercise / conversionCommon Stock | 2,593 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-009215 · form4.xml · nonDerivative · entry 1 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,169 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:52 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
GrantRestricted Stock Unit · Derivative | 64,745 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-009217 · form4.xml · derivative · entry 7 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,314 Underlying: Common Stock · 64,745 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F3 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:52 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 399,235 | $0.00 Strike: $57.92 | $0.00 |
DisclosureSEC source: 0001127602-22-009217 · form4.xml · derivative · entry 6 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 399,235 Underlying: Common Stock · 399,235 shares Expires 2032-03-10 F4 · derivative.exercise_date: The shares subject to the option have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:52 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 13,203 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-009217 · form4.xml · derivative · entry 5 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,569 Underlying: Common Stock · 13,203 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F3 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:52 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 10,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-009217 · form4.xml · derivative · entry 4 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,772 Underlying: Common Stock · 10,800 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:52 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
Tax withholdingCommon Stock | 11,052 | $57.92 | $640,131.84 |
DisclosureSEC source: 0001127602-22-009217 · form4.xml · nonDerivative · entry 3 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,344 Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:52 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
Exercise / conversionCommon Stock | 13,203 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-009217 · form4.xml · nonDerivative · entry 2 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,396 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:52 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
Exercise / conversionCommon Stock | 10,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-009217 · form4.xml · nonDerivative · entry 1 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,193 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 17:34 UTC |
Dickinson Andrew DChief Financial Officer
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 157,030 | $0.00 Strike: $57.92 | $0.00 |
DisclosureSEC source: 0001127602-22-009273 · form4.xml · derivative · entry 9 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,030 Underlying: Common Stock · 157,030 shares Expires 2032-03-10 F4 · derivative.exercise_date: The options have a four year vesting schedule. 25% vest on the first anniversary date of the date grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 17:34 UTC |
Dickinson Andrew DChief Financial Officer
|
GrantRestricted Stock Unit · Derivative | 25,465 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-009273 · form4.xml · derivative · entry 8 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,124 Underlying: Common Stock · 25,465 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F3 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 17:34 UTC |
Dickinson Andrew DChief Financial Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 4,108 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-009273 · form4.xml · derivative · entry 7 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,659 Underlying: Common Stock · 4,108 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F3 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 17:34 UTC |
Dickinson Andrew DChief Financial Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 3,025 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-009273 · form4.xml · derivative · entry 6 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,767 Underlying: Common Stock · 3,025 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 17:34 UTC |
Dickinson Andrew DChief Financial Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 768 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-009273 · form4.xml · derivative · entry 5 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,792 Underlying: Common Stock · 768 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 17:34 UTC |
Dickinson Andrew DChief Financial Officer
|
Tax withholdingCommon Stock | 3,602 | $57.92 | $208,627.84 |
DisclosureSEC source: 0001127602-22-009273 · form4.xml · nonDerivative · entry 4 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,005 Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 17:34 UTC |
Dickinson Andrew DChief Financial Officer
|
Exercise / conversionCommon Stock | 4,108 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-009273 · form4.xml · nonDerivative · entry 3 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,607 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 17:34 UTC |
Dickinson Andrew DChief Financial Officer
|
Exercise / conversionCommon Stock | 3,025 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-009273 · form4.xml · nonDerivative · entry 2 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,499 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 17:34 UTC |
Dickinson Andrew DChief Financial Officer
|
Exercise / conversionCommon Stock | 768 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-009273 · form4.xml · nonDerivative · entry 1 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,474 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 00:15 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 42,922 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-008127 · form4.xml · derivative · entry 5 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,572 Underlying: Common Stock · 42,922 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: The restricted stock units have a three year vesting schedule. 1/3 vest on each yearly anniversary of the date of grant until fully vested. F3 · derivative.expiration_date: The restricted stock units have a three year vesting schedule. 1/3 vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 00:15 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 11,362 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-008127 · form4.xml · derivative · entry 4 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,494 Underlying: Common Stock · 11,362 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 00:15 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
Tax withholdingCommon Stock | 23,245 | $60.26 | $1,400,743.70 |
DisclosureSEC source: 0001127602-22-008127 · form4.xml · nonDerivative · entry 3 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,393 Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 00:15 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
Exercise / conversionCommon Stock | 42,922 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-008127 · form4.xml · nonDerivative · entry 2 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,638 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 00:15 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
Exercise / conversionCommon Stock | 11,362 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-008127 · form4.xml · nonDerivative · entry 1 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,716 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| February 15, 2022 Filed Apr 14, 2022 00:32 UTC |
Parsey MerdadChief Medical Officer
|
GrantCommon Stock | 348 | $52.13 | $18,141.41 |
DisclosureSEC source: 0001127602-22-011953 · form4.xml · nonDerivative · entry 1 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,613 F1 · shares: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Gilead Sciences, Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of August 16, 2021 through February 15, 2022. This transaction is exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on February 15, 2022. Read SEC document |
| February 15, 2022 Filed Apr 14, 2022 00:34 UTC |
Pletcher Brett AEVP,Corp Affairs & Gen Counsel
|
GrantCommon Stock | 348 | $52.13 | $18,141.41 |
DisclosureSEC source: 0001127602-22-011955 · form4.xml · nonDerivative · entry 1 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,924 F1 · shares: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Gilead Sciences, Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of August 16, 2021 through February 15, 2022. This transaction is exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on February 15, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.